Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Subscribe To Our Newsletter & Stay Updated
